1. Introduction {#sec1}
===============

From the first HIV case detected in 1990 to June 30, 2016, there were 227,225 reported cases of HIV infection in Vietnam, of which the number of patients turned to AIDS was 85,753, and 89,210 HIV/AIDS infected cases died \[[@B1]\]. Since 2010, the World Health Organization (WHO) recommended tenofovir disoproxil fumarate (TDF) containing regimens for the treatment of HIV-infected patients; it was then used widespread and had officially become the preferred regimen \[[@B2]\] in Vietnam, since 2011, under the Decision 4139/QD-BYT of the Ministry of Health on amending and supplementing the guidelines for HIV/AIDS diagnosis and treatment. Accordingly, TDF, Lamivudine, and Efavirenz (TDF + 3TC + EFV) are the preferred treatment regimens for HIV/AIDS patients starting antiretroviral therapy (ARV), and now ARV regimens containing TDF are considered a top priority \[[@B3], [@B4]\]. Recently, Tenofovir alafenamide (TAF) has been accepted for use in several countries \[[@B5]\], although it has been proved to have an improved renal safety compared to TDF, if made available, in rural limited resources settings where regular renal function monitoring may be unrealistic \[[@B5]\]. According to Decision No. 5418/QD-BYT dated December 1, 2017 \[[@B3]\] of the Ministry of Health, Vietnam on issuing guidance for HIV/AIDs treatment and care, TAF has not yet been used for regular treatment in the health care centers in Vietnam. Besides, Abacavir was included in the treatment regime; it is often only assigned among HIV/AIDs children, coinfected with tuberculosis. Among adult HIV/AIDs patients, therefore, TDF is still quite popular in Vietnam.

Until December 31, 2018, Soc Trang had 1,204 patients on antiretroviral drugs (ARV), of which 88.2% used TDF-containing regimens and 98% of new patients received ARV in 2018 with TDF + 3TC + EFV regimen \[[@B6]\]. However, TDF induced nephrotoxicity cases have been reported \[[@B7]\], approximately 41% of patients taking TDF based regimen after 10 years treatment, which resulted in both acute kidney injury and chronic kidney disease occurring during treatment; cumulative events increased with duration of treatment \[[@B8]\]. According to Decision 5418/QD-BYT of the Ministry of Health in 2017 stipulating monitoring serum creatinine test before and during ARV treatment, this test was performed every 6--12 months or when renal dysfunction was suspected \[[@B3], [@B4]\]. Many studies showed that old age, low BMI, gender, CD4 less than 200 cells/mm^3^, long duration of HIV infection, WHO stage, and coinfection with hepatitis B and hepatitis C were risk factors for renal dysfunction \[[@B8]--[@B17]\]. A study has only followed up HIV patients treated with TDF based regimen within a duration of 24 months \[[@B9]\]. Little is known about the prevalence of renal impairment and risk factors among HIV-infected patients treated with TDF based regimen greater than 3 years. Our descriptive cross-sectional study aimed to estimate the prevalence and determine the correlation of renal impairment among this population.

2. Materials and Methods {#sec2}
========================

This is a cross-sectional study conducted in the department of infectious diseases, general hospital, Soc Trang Province from November 2018 to March 2019. The study protocol was reviewed and approved by the review board of the general hospital, Soc Trang Province on October 25, 2018. All participants provided written informed consent forms.

2.1. Study Population and Study Design {#sec2.1}
--------------------------------------

The target population of this study was HIV-infected patients, excluding pregnant women, who voluntarily participated in this study, aged over 18 years, had eGFR greater than 60 ml/min/1.73 m^2^, and were treatment-naive or switched TDF regimen within over 3 years. The study was powered to obtain 80% power with a two-sided 5% significant level for estimating the overall prevalence of 50% with the desired precision of 5%, which required 384 HIV-infected patients; this was rounded up 400 to allow approximately 5% participant refusal and specimen damage rate ([Figure 1](#fig1){ref-type="fig"}).

This study followed two-stage recruitment strategy. First, based on the list of patients who received antiretroviral treatment at study setting (estimated 865 participants), we filtered all patients using TDF regimen over 36 months since July first, 2018 (approximately 435 participants). Second, we recruited participants admitted to the hospital for reexamination to collect data and take blood samples based on the treatment-naive regime until we recruited enough 400 participants.

2.2. Demographic Collection {#sec2.2}
---------------------------

The information sheet describing the purpose and method was shown to participants, and after giving informed consent, we collected baseline demographic and clinical data from medical records including sex, age, weight, height, HIV transmission, WHO stage, tested time for HIV positive, treatment time, cotrimoxazole, isoniazid, viral load, baseline CD4 count, baseline serum creatinine, ALT, AST, hepatitis B, hepatitis C, WHO stage in which treatment started, and baseline hemoglobin. Neither names nor detecting information like phone numbers or addresses were collected.

2.3. Specimen Collection {#sec2.3}
------------------------

After the completed physical examination, 03 mL blood specimens were collected and stored at −20°C and transported to the Center of Testing Calibration, University of Medicine and Pharmacy at Ho Chi Minh City for serum creatinine, ALT, AST analysis by chemistry analyzer (AU480, Beckman Coulter, USA). Hemoglobin (Unicel DxH 800, Beckman Coulter, USA), CD4 cell count (cell/mm^3^, measured by the FacsCount, Becton Dickinson), and viral load (COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test) testing were performed at general hospital Soc Trang, Center of HIV/AIDS prevention, Can Tho Province, and Pasteur Institute Ho Chi Minh City, Vietnam, respectively, between October 2018 and March 2019.

Measurement of weight and height: we used Health-scale weight scales and height ruler (made in Shanghai, China) to measure weight and height. Body mass index (BMI) was calculated as BMI = weight (in kg) ÷ (height (in m))^2^. According to the guideline of CKD EPI equation \[[@B18]\] to calculate the estimated glomerular filtration rate (eGFR) in HIV infected patients, serum creatinine values are used to calculate eGFR in the following equations below:For female with serum creatinine ≤0.7 mg/dl: GFR =166 × (Scr (in mg/dl)/0.7)^−0.329^ × (0.993)^Age\ (in\ year)^; female with serum creatinine \>0.7 mg/dl: GFR = 166× (Scr (in mg/dl)/0.7)^−1.209^ × (0.993)^Age\ (in\ year)^For male with serum creatinine ≤0.9 mg/dl: GFR =163 × (Scr (in mg/dl)/0.9)^−0.411^ × (0.993)^Age\ (in\ year)^; female with serum creatinine \>0.9 mg/dl: GFR = 163× (Scr (in mg/dl)/0.9)^−1.209^ × (0.993)^Age\ (in\ year)^

In this study, we used the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation to clarify the eGFR (ml/min/1.73 m^2^) group including 6 stages (stage 1 (\>90), stage 2 (60--89), stage 3a (45--59), stage 3b (30--44), stage 4 (15--29), and stage 5 (\<15)).

2.4. Statistical Analysis {#sec2.4}
-------------------------

All information sheets were checked for missing data and were stored in locked cabinets. Data were entered using Epi-Data version 3.1 (Epi-Data Association, Odense, Denmark), and all statistical analysis was implemented using Stata version 13.0 (StataCorp, TX), and *P*-value \< 0.05 was considered statistically significant.

The patient\'s characteristics were described using frequency and proportion for categorical variables and mean and standard deviation or median and interquartile ranges for continuous variables.

In this study, renal impairment was defined as eGFR less than 60 ml/min/1.73 m^2^ \[[@B13]\]. In the univariate analysis, we used Chi-squared and Fisher\'s exact tests to assess bivariate relationships. We used the prevalence ratio (PR) as a reliable and interpretable measure to predict renal impairment in the multivariate regression model. Variables that yielded a *P* less than 0.25 or were previously known to be an important risk factor in existing literature were included in multivariate analysis. In multivariate analysis, we used Poisson multivariate regression with backward elimination to detect the final model that describes contributing variables.

3. Results {#sec3}
==========

3.1. Demographic Characteristics {#sec3.1}
--------------------------------

A total of 400 participants were recruited in the present study. The mean (±SD) age was 39.8 (±8.8); 51.5% of respondents were male. The mean (±SD) age was 21.2 (±3.4).

3.2. Clinical Characteristics {#sec3.2}
-----------------------------

The majority of study participants suffered from HIV through sexuality (89.5%); up to 98.3% of respondents were found in the World Health Organization (WHO) stage 1, and fifty percent recorded WHO stage 3 for starting treatment.

The mean (±SD) time for HIV positive testing and treatment was 7.0 (±7.0); 6.5 (±2.5), respectively. Up to 93.5% and 94.7% of respondents were preexposed to isoniazid and cotrimoxazole preventive therapy. The majority of study participants had a viral load less than 20 copies per mL (93.5%), and the mean (±SD) CD4 count, serum creatinine *µ*mol/L, and hemoglobin (g/L) were 517 (±250), 75.7 (±18.2), and 13.5 (±1.6), respectively.

9.7% of study participants were with comorbidity of hepatitis B and hepatitis C (7.2%). Among study participants, approximately one-third had an AST \> 37 U/L and ALT \> 40 U/L, and 26.2% had an AST \> 37 U/L and ALT \> 40 U/L ([Table 1](#tab1){ref-type="table"}).

3.3. Renal Function Characteristics {#sec3.3}
-----------------------------------

In the present study, the mean (±SD) eGFR (ml/min/1.73 m^2^) was 96.0 (±24.5), 57.3% of respondents had baseline eGFR greater than 90 ml/min/1.73 m^2^, and none of them had had baseline eGFR less than 15 ml/min/1.73 m^2^, out of 34 (8.5%) of participants who had renal impairments ([Table 1](#tab1){ref-type="table"}).

3.4. Subclinical Characteristics and KDIGO 2012 {#sec3.4}
-----------------------------------------------

There were significant differences between the mean (±SD) baseline creatinine, eGFR, baseline CD4 count, and KDIGO stage among study participants (*P* \< 0.001). Compared with KDIGO stage 1, patients who were diagnosed with KDIGO stages 2, 3, and 4 had significantly higher mean (±SD) baseline creatinine (70.1 (±12.6) vs 77.5 (±13.7), 97.2 (±18.8), 151.6 (±51.5), 167.9 (±16.9)), respectively. By contrast, compared with KDIGO stage 1, those with KDIGO stages 2, 3, and 4 had significantly lower mean (±SD) baseline eGFR, (111.9 (±18.1) vs 80.3 (±6.6), 56.4 (±3.7), 40.7 (±3.9), 21.8 (±5.5)), and mean (±SD) CD4 count (531.5 (±233.8) vs 530.7 (±404.9), 470.2 (±251.2), 526.5 (±345.8), 130.7 (±24.4)), respectively ([Table 2](#tab2){ref-type="table"}).

3.5. Factors between Renal Impairment and Demographic and Clinical Characteristics among HIV/AIDS Patients {#sec3.5}
----------------------------------------------------------------------------------------------------------

In univariate analysis, renal impairment was more prevalent among older HIV/AIDS patients; those had higher WHO stage and baseline CD4 count less than 200 cells/mm^3^. The proportion of renal impairment was less prevalent among those who were preexposed to isoniazid, with BMI more than 18.5 kg/m^2^.

However, after they were adjusted with a multivariate regression model, only three factors were associated with renal impairment in the final model, including age group, preexposure to isoniazid, and BMI group. Patients who aged more than 60 years (adjusted PR \[aPR\] = 26.75, 95% Cl: 3.38--211.62) compared with those aged 20--29 years had significantly increased risk of renal impairment. Patients who had BMI ranging from 18.5 to 25 kg/m^2^ (aPR = 0.31 Cl: 0.15--0.62) compared to BMI less than 18.5 kg/m^2^ and who were preexposed to isoniazid (aPR = 0.35 Cl: 0.14--0.91) were less likely to suffer from renal impairment ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, we present findings from the renal impairment prevalence survey of semiurban HIV/AIDS patients conducted in southern Vietnam. A striking finding in this study is that participants who were preexposed to isoniazid and TDF were less likely to report renal impairment compared with those who were not preexposed to isoniazid. According to Decision No. 2495/QD-BYT dated July 18, 2012 \[[@B19]\], on issuing guidelines for active detection of tuberculosis and isoniazid prophylaxis in HIV infected patients; Decision No. 5418/QD-BYT dated December 1, 2017, on issuing HIV/AIDs treatment and care \[[@B3]\]; Decision No. 471/QD-BYT dated February 11, 2014, on issuing improving care and treatment quality among HIV infected patients of the Ministry of Health, Vietnam, HIV infected patients were screened for tuberculosis on each visit. In this study, 40 (10%) of the participants were coinfected with tuberculosis in which 379 (94.7%) had a cough, fever, night sweats, and weight loss; all of them were provided isoniazid prophylaxis for 9 months. Although some studies reported the influence of renal impairment on isoniazid use among tuberculosis patients \[[@B20], [@B21]\], a scarcity of evidence showed that isoniazid use affected renal function among HIV/AIDS treated with TDF regimen. Thus, the impact of preexposure to isoniazid and TDF should be carefully considered in patients for long-time monitoring of renal function.

We also found a low prevalence of renal impairment among study participants. This finding was consistent with findings in South Africa (7.6%) \[[@B13]\] and Malaysia 9.3% \[[@B17]\], lower than in Korean (14.4%) \[[@B22]\] and Japan (22.1%) \[[@B12]\], and higher than in Spain (4-5%) \[[@B23]\]. This could be explained that differences in genetic factors correlated with an inherited polymorphism in drug transporter proteins of the renal tubule which led to TDF accumulation in the proximal tubular cells \[[@B24], [@B25]\], and several studies also showed that HIV affected direct renal pathogenic role \[[@B13], [@B26], [@B27]\].

In the current study, we also found that patients who had low BMI were significantly associated with renal impairment compared with those who had normal BMI; this result was similar to studies conducted in Vietnam and Japan \[[@B9], [@B28], [@B29]\], but in contrast to the study conducted in Ethiopia \[[@B25]\]. It may be different sample sizes \[[@B25]\], duration of study time, as a little is known about BMI effect on renal function on the long term \[[@B9]\]; therefore, the need for deep and long-term research should be taken into account.

As shown in our study, we did not find the relationship between cotrimoxazole, hepatitis B, C virus infection, and renal impairment which was consistent with the study conducted in Vietnam \[[@B9]\]; however, these predictors could be affected by renal impairment \[[@B30], [@B31]\]. There may have been a difference in exclusion criteria in these studies due to the study design; therefore, participants affected by these risk factors could be excepted \[[@B9]\].

Compared with patients aged 20--29 years, patients with ages equal to and greater than 60 years were more likely to report renal impairment. This finding was in agreement with studies conducted in Ethiopia \[[@B25]\] and Malaysia \[[@B10]\], which showed that old age was considered to be a risk factor for TDF induced nephrotoxicity. It is known that kidney function and structure would deteriorate by age \[[@B25], [@B32]\].

In the univariate analysis, we found that baseline CD4 count less than 200 cell/mm^3^ was significantly associated with renal impairment, which was in line with the previous studies \[[@B25], [@B33], [@B34]\]. But in multivariate analysis, baseline CD4 count was not a risk factor; this may be partly explained by the fact that participants in the present study were receiving stable HIV treatment. However, lower baseline CD4 count was a predominant factor associated with kidney injury \[[@B25], [@B35]\].

The current study was the first study to assess the risk factors among participants who were treated with ARV based TDF regimen over 3 years in Vietnam. However, there are several limitations. In this present study, we did not collect urine data for analysis so that we could not assess chronic kidney disease among participants \[[@B36]\]. In a rural resource-limited setting of Soc Trang, Vietnam, proteinuria was not routinely measured, although proteinuria is frequently detected in HIV infected patients, with approximately thirty percent showing microalbuminuria despite normal serum creatinine levels \[[@B37]\]. In HIV infected patients, proteinuria is more likely to be progressing to AIDS and death. It could be explained that HIV-associated nephropathy demonstrates as rapidly progressive renal disease, associated with the severity of proteinuria levels and direct HIV infection of renal tissue \[[@B38]\]. Therefore the lack of infrastructure for such regular monitoring can make early detection of renal toxicity among HIV infected patients difficult to follow \[[@B6]\]. We recommended that routine proteinuria screening of all new patients should be taken into account at primary health care. Furthermore, due to cross-sectional design, we could only find the risk factors associated with renal impairment, but could not determine the causative association between TDF and renal function \[[@B29]\].

This survey has important implications for the prioritized strategies for the prevention of renal impairment as TDF is still an important drug for HIV-infected patients \[[@B9]\]. This study indicated low BMI, old age, and no exposure to isoniazid among HIV-infected patients treated with ARV based on TDF, which are primary risk factors for renal impairment. We strongly recommend the need for longitudinal studies to assess the influence of TDF on renal impairment.

5. Conclusion {#sec5}
=============

Our findings underscore the need for longitudinal studies to assess the influence of TDF to maintain the low prevalence of renal impairment among HIV-infected patients in Vietnam.
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###### 

Demographic, clinical characteristic among HIV-infected patients in Soc Trang, Vietnam.

  Characteristics                                          Frequency (*n* = 400)   Percentage (%)
  -------------------------------------------------------- ----------------------- -----------------------
  Sex                                                                              
   Male                                                    206                     51.5
   Female                                                  194                     48.5
  Age (in year)                                            39.8 ± 8.8              Min: 20--max: 69
  Age group                                                                        
   20--29                                                  38                      9.5
   30--39                                                  181                     45.2
   40--49                                                  127                     31.8
   50--59                                                  43                      10.8
   ≥ 60                                                    11                      2.7
  BMI (in kg/m^2^)                                         21.2 ± 3.4              Min: 12.9--max: 35.0
  BMI group                                                                        
   \<18.5                                                  85                      21.2
   18.5--25                                                268                     67.0
   \>25                                                    47                      11.8
  HIV transmission                                                                 
   Drug addiction                                          30                      7.5
   Sexuality                                               358                     89.5
   Mother to child                                         12                      3.00
  WHO stage (current)                                                              
   Stage 1                                                 393                     98.3
   Stage 2                                                 3                       0.7
   Stage 3                                                 2                       0.5
   Stage 4                                                 2                       0.5
  Interval of HIV infection after diagnosis (years)        7.0 ± 7.0               Min: 4--max: 20
  Interval of HIV infection after diagnosis group (year)   7.0 ± 7.0               Min: 4--max: 20
   \<5                                                     87                      21.8
   5--10                                                   266                     66.5
   11--15                                                  44                      11.0
   \>15                                                    3                       0.7
  Treatment time (year)                                    6.5 ± 2.5               Min: 3--max: 18
   3--5                                                    168                     42.0
   6--10                                                   199                     49.7
   \>10                                                    33                      8.3
  Preexposure to cotrimoxazole                                                     
   Yes                                                     374                     93.5
   No                                                      26                      6.5
  Preexposure to isoniazid                                                         
   Yes                                                     379                     94.7
   No                                                      21                      5.3
  Viral load (\<20 copies/ml)                                                       
   Yes                                                     374                     93.5
   No                                                      26                      6.5
  Baseline CD4 count (cells/mm^3^)                         517.0 ± 250             Min: 37--max: 1691
   \>500 CD4 count                                         193                     48.3
   350--499 CD4 count                                      102                     25.5
   200--349 CD4 count                                      82                      20.5
   \<200 CD4 count                                         23                      5.7
  Baseline serum creatinine (*µ*mol/L)                     75.7 ± 18.2             Min: 45.7--max: 188
  Baseline eGFR (ml/min/1.73 m^2^)                         96.0 ± 24.5             Min: 15.8--max: 177.6
   Stage 1 (\>90)                                          229                     57.3
   Stage 2 (60--89)                                        137                     34.2
   Stage 3a (45--59)                                       29                      7.2
   Stage 3b (30--44)                                       2                       0.5
   Stage 4 (15--29)                                        3                       0.8
   Stage 5 (\<15)                                          0                       0.0
  AST (\>37 U/L)                                                                   
   Yes                                                     138                     34.5
   No                                                      262                     65.5
  ALT (\>40 U/L)                                                                   
   Yes                                                     140                     35.0
   No                                                      260                     65.0
  AST (\>37 U/L) and ALT (\>40 U/L)                                                
   Yes                                                     105                     26.2
   No                                                      285                     73.8
  Hepatitis B                                                                      
   Yes                                                     39                      9.7
   No                                                      361                     91.3
  Hepatitis C                                                                      
   Yes                                                     29                      7.2
   No                                                      371                     92.8
  WHO stage (started treatment)                                                    
   Stage 1                                                 69                      17.3
   Stage 2                                                 44                      11.0
   Stage 3                                                 200                     50.0
   Stage 4                                                 87                      21.7
  Baseline hemoglobin (g/L)                                13.5 ± 1.6              Min: 6.8--max: 17.1
  eGFR categories (mL/min/1.73 m^2^)                                                
   Stage 1 (\>90)                                          229                     57.2
   Stage 2 (60--89)                                        137                     34.2
   Stage 3a (45--59)                                       29                      7.3
   Stage 3b (30--44)                                       2                       0.5
   Stage 4 (15--29)                                        3                       0.8
   Stage 5 (\<15)                                          0                       0.0

###### 

Subclinical stages according to Kidney Disease Improving Global Outcomes (KDIGO) 2012 among HIV-infected patients in Soc Trang, Vietnam.

  Variables    KDIGO 2012      *P*                                                            
  ------------ --------------- --------------- --------------- --------------- -------------- --------
  Creatinine   70.1 ± 12.6     77.5 ± 13.7     97.2 ± 18.8     151.6 ± 51.5    167.9 ± 16.9   \<0.01
  eGFR         111.9 ± 18.1    80.3 ± 6.6      56.4 ± 3.7      40.7 ± 3.9      21.8 ± 5.5     \<0.01
  AST          41.6 ± 37.8     38.4 ± 27.2     34.4 ± 12.4     53.4 ± 12.8     71.6 ± 59.5    0.16
  ALT          44.4 ± 42.2     37.9 ± 28.1     31.8 ± 17.3     74.2 ± 69.4     62.9 ± 33.1    0.14
  Hb           13.6 ± 1.7      13.4 ± 1.6      13.4 ± 1.3      14.3 ± 0.7      12.5 ± 0.7     0.25
  CD4 count    531.5 ± 233.8   530.7 ± 404.9   470.2 ± 251.2   526.5 ± 345.8   130.7 ± 24.4   0.02

###### 

Predictors for renal impairment (KDIGO 2012) among HIV-infected patients in Soc Trang, Vietnam, with univariate and multivariate models.

  Variables                              Renal impairment % for each category   Univariate analysis   Multivariate analysis                                       
  -------------------------------------- -------------------------------------- --------------------- ----------------------- --------- ------------------------- -------------------------
  Sex                                                                                                                                                             
   Female                                194                                    16                    8.3                     0.860     Ref                        
   Male                                  206                                    18                    8.7                               1.06 (0.54--2.08)          
  Age group                                                                                                                                                       
   20--29                                38                                     1                     2.6                     \<0.001   Ref                       Ref
   30--39                                181                                    7                     3.9                               1.47 (0.18--11.94)        1.35 (0.16--11.01)
   40--49                                127                                    6                     4.7                               1.79 (0.22--14.91)        2.06 (0.14--17.14)
   50--59                                43                                     11                    25.6                              9.72 (1.25--75.29)^¥^     7.72 (0.99--60.14)
  ≥60                                    11                                     9                     81.8                              31.09 (3.94--245.40)^§^   26.75 (3.38--211.62)^¥^
  HIV transmission                                                                                                                                                
   Drug addition                         30                                     2                     6.7                     0.510     Ref                        
   Sexuality                             358                                    32                    8.9                               1.34 (0.32--5.59)          
   Mother to child                       12                                     0                     0.0                               ---                        
  BMI                                                                                                                                                             
   \<18.5                                85                                     18                    21.2                    \<0.001   Ref                       Ref
   18.5--25                              268                                    15                    5.6                               0.26 (0.13--0.75)^¥^      0.31 (0.15--0.62)^¥^
   \>25                                  47                                     1                     2.1                               0.13 (1.33--0.52)^¥^      0.19 (0.02--1.48)
  WHO stage (current)                                                                                                                                             
   Stage 1                               393                                    29                    7.4                     \<0.001   Ref                       Ref
   Stage 2                               3                                      2                     66.7                              9.03 (2.15--37.86)^§^     1.88 (0.24--14.94)
   Stage 3                               2                                      2                     100.0                             13.55 (3.23--56.79)^§^    1.67 (0.20--14.12)
   Stage 4                               2                                      1                     50.0                              6.77 (0.92--49.74)        2.40 (0.24--24.09)
  Tested time for HIV positive (years)                                                                                                                            
   \<5                                   87                                     9                     10.3                    0.840     Ref                        
   5--10                                 266                                    21                    7.9                               1.31 (0.60--2.86)          
   11--15                                44                                     4                     9.1                               1.15 (0.40--3.35)          
   \>15                                  3                                      0                     0.0                               ---                        
  Treatment time                                                                                                                                                  
   3--5                                  168                                    14                    8.3                     0.980     Ref                        
   6--10                                 199                                    17                    8.5                               1.02 (0.50--2.08)          
   \>10                                  33                                     3                     9.1                               1.09 (0.31--3.79)          
  Preexposure to cotrimoxazole                                                                                                                                    
   No                                    26                                     3                     11.5                    0.560     Ref                        
   Yes                                   374                                    31                    8.3                               0.72 (0.22--2.34)          
  Preexposure to isoniazid                                                                                                                                        
   No                                    21                                     5                     23.8                    0.010     Ref                       Ref
   Yes                                   379                                    29                    7.7                               0.32 (0.12--0.83)^¥^      0.35 (0.14--0.91)^¥^
  Viral load (\<20 copies/ml)                                                                                                                                     
   Yes                                   374                                    31                    8.3                     0.560     Ref                        
   No                                    26                                     3                     11.5                              0.72 (0.22--2.35)          
  Baseline CD4 count (cells/mm^3^)                                                                                                                                
   \>500 CD4 count                       193                                    15                    7.8                     0.002     Ref                       Ref
   350--499 CD4 count                    102                                    3                     2.9                               0.38 (0.11--1.31)         1.93 (0.43--8.73)
   200--349 CD4 count                    82                                     10                    12.2                              1.57 (0.70--3.49)         0.61 (0.10--3.71)
   \<200 CD4 count                       23                                     6                     26.1                              3.35 (1.30--8.65)^¥^      1.20 (0.28--5.20)
  AST (\>37 U/L)                                                                                                                                                  
   No                                    262                                    19                    7.3                     0.210     Ref                        
   Yes                                   138                                    15                    10.9                              1.50 (0.76--2.94)          
  ALT (\>40 U/L)                                                                                                                                                  
   No                                    260                                    25                    9.6                     0.270     Ref                        
   Yes                                   140                                    9                     6.4                               0.67 (0.31--1.43)          
  AST (\>37 U/L) and ALT (\>40 U/L)                                                                                                                               
   No                                    295                                    27                    9.2                     0.430     Ref                        
   Yes                                   105                                    7                     6.7                               0.73 (0.31--1.67)          
  Hemoglobin (\>16 g/L)                                                                                                                                           
   No                                    377                                    33                    8.8                     0.460     Ref                        
   Yes                                   23                                     1                     4.4                               0.49 (0.68--3.36)          
  Hemoglobin (\<12 g/L)                                                                                                                                           
   No                                    340                                    29                    8.5                     0.960     Ref                        
   Yes                                   60                                     5                     8.3                               0.97 (0.38--2.52)          
  WHO stage (started treatment)                                                                                                                                   
   Stage 1                               69                                     1                     1.5                     0.130     Ref                        
   Stage 2                               44                                     5                     11.4                              7.84 (0.92--67.11)         
   Stage 3                               200                                    19                    9.5                               6.55 (0.87--48.96)         
   Stage 4                               87                                     9                     10.3                              7.14 (0.90--56.34)         
  Hepatitis B                                                                                                                                                     
   No                                    361                                    32                    8.9                     0.427     Ref                        
   Yes                                   39                                     2                     5.1                               1.58 (0.14--2.41)          
  Hepatitis C                                                                                                                                                     
   No                                    371                                    32                    8.6                     0.750     Ref                        
   Yes                                   29                                     2                     6.9                               0.80 (0.19--3.33)          

^¥^\<0.05. ^§^\<0.001. aPR: adjusted prevalence ratio.

[^1]: Academic Editor: Josep-Maria Llibre
